Since TNFR1 has been implicated to play a major role in NAFLD-associated liver injury, we analyzed potential therapeutic effects of an antagonistic huTNFR1-selective antibody27–29. This evidence concerns the gene TNFRSF1A and metabolic dysfunction-associated steatotic liver disease.